EntryPoint Capital LLC Makes New $655,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

EntryPoint Capital LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 12,225 shares of the company’s stock, valued at approximately $655,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Avanza Fonder AB acquired a new position in Janux Therapeutics during the 4th quarter valued at about $139,000. Chicago Capital LLC acquired a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $230,000. Legato Capital Management LLC acquired a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $347,000. Y Intercept Hong Kong Ltd bought a new position in Janux Therapeutics in the 3rd quarter worth approximately $317,000. Finally, Virtu Financial LLC increased its position in Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 293,054 shares in the company, valued at $17,583,240. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,002 shares of company stock valued at $1,279,953 over the last ninety days. Corporate insiders own 29.40% of the company’s stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of several recent analyst reports. Leerink Partners increased their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. BTIG Research boosted their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Stifel Nicolaus raised their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of “Buy” and an average target price of $92.44.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $31.74 on Tuesday. The company has a market capitalization of $1.88 billion, a PE ratio of -27.13 and a beta of 3.23. The stock has a fifty day moving average of $36.62 and a 200-day moving average of $46.38. Janux Therapeutics, Inc. has a one year low of $28.92 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.